Odyral Pf (Dorzolamide)

Odyral Pf (dorzolamide) is used in the management of ocular conditions characterized by elevated intra‑ocular pressure.

• Primary open-angle glaucoma: reduces intra‑ocular pressure to help prevent progressive optic nerve damage.
• Ocular hypertension: lowers intra‑ocular pressure, decreasing the risk of developing glaucoma.
• Secondary glaucoma: decreases aqueous humor production, aiding pressure control in secondary forms of glaucoma.
• Glaucoma patients unsuitable for beta‑blocker therapy: offers a non‑beta‑blocker option for intra‑ocular pressure reduction.

• Dorzolamide selectively inhibits carbonic anhydrase isoenzymes in the ciliary epithelium of the eye. By blocking this enzyme, the production of aqueous humor is reduced, leading to a decrease in intra‑ocular pressure. The effect is localized to the ocular tissues, minimizing systemic exposure, and the inhibition is reversible, allowing intra‑ocular pressure to be titrated according to therapeutic need.

Adverse ocular reactions have been reported with dorzolamide ophthalmic solution.

Common Side Effects

• Eye irritation or burning sensation: mild discomfort that usually resolves quickly.
• Bitter taste after administration: transient metallic taste perceived after the drop.
• Blurred vision: temporary visual disturbance lasting minutes.
• Transient headache: mild headache occurring shortly after use.

Serious or Rare Side Effects

• Severe allergic reaction (e.g., angio‑edema, anaphylaxis): requires immediate medical attention.
• Persistent eye pain or inflammation: may indicate a serious ocular event.
• Vision loss: sudden decrease in visual acuity, seek urgent care.

Before using Odyral Pf, consider the following precautions to ensure safe and effective therapy.

• Pregnancy: safety not established; use only if benefits outweigh risks.
• Breastfeeding: unknown excretion; evaluate risk versus benefit.
• Contact lens wearers: may cause discomfort; remove lenses before instillation and wait before reinserting.
• Systemic carbonic anhydrase inhibitors: concurrent use may increase risk of systemic side effects.
• Known hypersensitivity: discontinue if allergic reaction occurs.
• Store at room temperature: keep in original container, protect from light and moisture.

Dorzolamide may interact with other medications; be aware of the following potential interactions.

Major Interactions (Avoid)

• Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): additive inhibition may increase systemic side effects.
• Sulfonamide antibiotics (e.g., sulfamethoxazole): cross‑reactivity risk for patients with sulfonamide allergy.

Moderate Interactions (Monitor Closely)

• Topical non‑steroidal anti‑inflammatory drugs: may increase ocular irritation.
• Other intra‑ocular pressure‑lowering agents (e.g., beta‑blocker eye drops): monitor for excessive pressure reduction.
• Oral potassium‑sparing diuretics: may potentiate systemic electrolyte disturbances.